The CASMI Translational Stem Cell Consortium (CTSCC) aims to be a global nexus for pluripotent stem cell translation. This flagship CASMI project was established in response to the disconnect between academic early stage research and later stage commercial entities with the hope of accelerating the commercialisation and clinical adoption of pluripotent stem cell therapeutics.
Acting in principally pre-competitive areas of stem cell translation, the CTSCC engages and combines contributions from world leading academic and industrial partners in response to commercially pressing challenges posed by its funding partners.
The transformative work of the CASMI Translational Stem Cell Consortium is supported by the Californian Institute for Regenerative Medicine (CIRM), Sartorius Stedim Biotech Group, NIH Center for Regenerative Medicine, SENS Research Foundation, Lonza, UK Cell Therapy Catapult, GE Healthcare, Canadian Centre for the Commercialization of Regenerative Medicine (CCRM), ThermoFisher Scientific, Meidpost, Celgene, Eisai, and the New York Stem Cell Foundation (NYSCF).
The CTSCC is co-ordinated by David Brindley, University of Oxford (NDORMS), CASMI and the Harvard Stem Cell Institute. Dr. Ivan Wall (UCL) and Prof. Zhanfeng Cui (University of Oxford) act as the Academic Leads, representing CASMI’s two founding institutions, with Mr. Brock Reeve (Harvard Stem Cell Institute) as the CTSCC’s International Academic Lead. The work of the CTSCC presently focuses on the following five areas:
– Standards (Focus Area Lead- Anna French, University of Oxford)
– Biomanufacturing (Focus Area Lead- Kim Bure, TAP Biosystems)
– Strategic Partnerships (Focus Area Lead- Brock Reeve, Harvard Stem Cell Institute)
– Regulation and IP (Focus Area Lead- Christopher Bravery, Consulting on Advanced Biologics Ltd.)
– Surgical (Focus Area Lead- Ben Davies, Oxford NDORMS)
The CTSCC is a rapidly growing global influencer, producing high-impact academic publications and productive international meetings that provide a forum for leaders from across the translational spectrum to collaboratively foster advancement. The Consortium launched officially at a major European meeting in July 2013 (click here for the full report).
In summary, the CTSCC aims to address the unacceptable status quo in global pluripotent stem cell translation and bring critical therapeutics to market sooner for patients with clinically unmet needs.
For further information please contact the Consortium Co-ordinator, David Brindley. Email David Brindley